CTLA4 and B-cell non-Hodgkin lymphoma: These cells are enriched in negative immune regulators like CTLA-4 and therefore CTLA-4 blockade with ipilimumab was studied in a phase 1 trial for patients with relapsed/refractory B cell NHL.